Prostatic Neoplasms Clinical Trial
Official title:
Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship
The investigators conduct this prospective study to investigate the learning curve of digital rectal examination (DRE) for prostate cancer among internship. The investigators want to know how many DRE are usually needed for internship to be performed in urological practice to obtain a stable DRE accuracy.
Status | Recruiting |
Enrollment | 700 |
Est. completion date | February 26, 2019 |
Est. primary completion date | February 26, 2019 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - Internship just graduate from the medical school, and agree to attend the study. - Internship have less than 5 DREs of prostate cancer. - Patients of any age who are included for prostate biopsy are eligible, the indications for prostate biopsy are as follows: PSA>4ng/ml, fPSA/tPSA<0.16, with suspected palpable nodes in the prostate by DRE of attending doctor, suspected mass in prostate detected by ultrasound examination, magnetic resonance imaging, or computed tomography. Exclusion Criteria: - Internship who are not willing to attend the study. - Internship stop doing DRE for continuously 3 months after entering the study. |
Country | Name | City | State |
---|---|---|---|
China | Changhai Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Changhai Hospital |
China,
Clements MB, Schmidt KM, Canfield SE, Gilbert SM, Khandelwal SR, Koontz BF, Lallas CD, Liauw S, Nguyen PL, Showalter TN, Trabulsi EJ, Cathro HP, Schenkman NS, Krupski TL. Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. J Surg Educ. 2018 Mar - Apr;75(2):434-441. doi: 10.1016/j.jsurg.2017.08.012. Epub 2017 Oct 12. — View Citation
Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, Vickers AJ, Hu JC. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. J Urol. 2017 Oct 20. pii: S0022-5347(17)77762-2. doi: 10.1016/j.juro.2017.10.021. [Epub ahead of print] — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity and specificity of DRE performed by internship will be confirmed by prostate biopsy | To examine the sensitivity and specificity of the DRE performed by internship to reference standard of prostate biopsy in a prospective longitudinal cohort of around 700 participants who will undergo prostate biopsy due to suspect of prostate cancer. The investigators will investigate the sensitivity and specificity of DRE by different internship monthly. | One year | |
Secondary | Sensitivity and specificity of DRE performed by internship with different training plan will be confirmed by prostate biopsy | To examine the sensitivity and specificity of the DRE performed by internship (group 1 with routinely review of pathologic outcome of prostate biopsy twice a month, and group 2 internship who are not told the results of prostate biopsy) to standard reference of prostate biopsy. | One year | |
Secondary | Sensitivity and specificity of DRE performed by internship will be compared to the results of fPSA/tPSA and MRI. | To compare the sensitivity and specificity of DRE to fPSA/tPSA and MRI (not any patients are required to have MRI examination of prostate, this will be determined at the discretion of attending doctor) to reference standard of prostate biopsy. | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04964271 -
Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
|
||
Completed |
NCT02546908 -
A Registry of Participants With Prostate Cancer in Asia
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT01683994 -
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04838613 -
Study of Diagnostic Performance of [18F]CTT1057 in BCR
|
Phase 3 | |
Completed |
NCT02364531 -
A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
|
||
Completed |
NCT01929655 -
Japanese BAY88-8223 Monotherapy Phase II Study
|
Phase 2 | |
Active, not recruiting |
NCT05022849 -
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
|
Phase 1 | |
Completed |
NCT03261999 -
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
|
Phase 3 | |
Terminated |
NCT04907227 -
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension
|
Phase 3 | |
Active, not recruiting |
NCT03587285 -
A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02217566 -
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04101305 -
Measurement of Circulating Tumor Cells in Prostate Cancer
|
||
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Withdrawn |
NCT02905201 -
A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
|
N/A | |
Terminated |
NCT03066154 -
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
|
Phase 1 | |
Completed |
NCT02692976 -
Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients
|
Phase 2 | |
Terminated |
NCT01420965 -
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
|
Phase 2 | |
Completed |
NCT01441713 -
Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer
|
N/A |